NuCana plc
Research NuCana plc (NCNA) on Bullrun: market cap USD 4.74M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNCNA
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.74M
- Financial periodQ2 2026
- RevenueGBP 0
- Net income-GBP 3.08M
- Free cash flow-GBP 2.10M
Valuation Snapshot
latest market cap is USD 4.74M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 29.35M | -GBP 7.66M | n/a | 0 | GBP 24.25M | GBP 676.00K | GBP 24.33M |
| FY2024 | GBP 0 | -GBP 19.00M | -GBP 19.41M | n/a | -1300 | GBP 6.75M | GBP 190.00K | GBP 5.95M |
| FY2023 | GBP 0 | -GBP 27.63M | -GBP 26.92M | n/a | -2650 | GBP 17.23M | GBP 396.00K | GBP 14.89M |
| FY2022 | GBP 0 | -GBP 32.02M | -GBP 23.68M | n/a | -3050 | GBP 41.91M | GBP 639.00K | GBP 38.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 4.74M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.98M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.74M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 15.54M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 34.32M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 123.76M | n/a | n/a | n/a |
About NuCana plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NuCana plc's market cap?
NuCana plc's market capitalization is USD 4.74M.
What does NuCana plc do?
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells.